Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine in ALS (HEALEY Platform Regimen D)
NCT04615923Phase 3Completed
- Start
- Dec 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Pridopidine with Matching Placebo (2 arms). Primary endpoints: Disease Progression as Assessed by the ALSFRS-R Total Score at 24 weeks and Mortality Event Rate at 24 weeks. Started Dec 2020; status: completed.
02
Drugs
pridopidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04615923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615923.